Category: Research & Development
By Merrill Goozner
Much has been written about the travails of the pharmaceutical industry. Generic competition is reducing profitability as leading blockbuster drugs like Pfizer's Lipitor lose patent protection. Biotech generic competition is on the horizon.
Disappearing stent technology makes waves at this year's EuroPCR conference in Paris, with Elixir Medial touting its fully bioabsorbable coronary scaffold and Terumo and Biotronik unveiling results for their stents with a bioerodable polymer coatings.
Disappearing technology had a strong presence at this year's EuroPCR conference in Paris, with rival device makers demonstrating the safety and efficacy of their next-generation stents.
Elixir Medical unveiled 1st-in-man clinical results for its DESolve fully bioabsorbable drug-eluting scaffold system, a stent made from a proprietary polymer and coated in novolimus. The entire stent is designed to be absorbed by the body in 1-2 years.
St. Jude Medical's newly CE Marked Enlightn renal denervation system boasts twice the reduction in blood pressure after 1 month compared with rival technologies.
St. Jude Medical's (NYSE:STJ) newly cleared Enlightn renal denervation system lowered patients' blood pressure by twice as much as rival systems in the same amount of time, according to a new study.
Preliminary findings from a study of the Enlightn system found that patients with hypertension saw a 28 point reduction in blood pressure after 30 days.
Transcatheter aortic valve implantation proves successful in reinforcing failed valve prosthetics, but researchers warn against making it a common practice.
Although patients may benefit from having a failed aortic valve prosthetic reinforced via transcatheter aortic valve implantation, researchers warned against making the procedure a common practice.
St. Jude Medical calms physicians' fears about the new Durata ICD leads in the face of the ongoing Riata recall and unveils results from a decade-long follow-up of patients with implantable cardiac defibrillators.
St. Jude Medical (NYSE:STJ) tried to distance its Durata defibrillator leads from their troubled Riata predecessor and unveiled the results of the decade-long SCD-HeFT heart failure study during separate presentations at this year's Heart Rhythm Society meeting in Boston, Mass.
The contentious fracas between DePuy and a researcher over a study published in the British Medical Journal may be a preview of the company's arguments in court.
The quarrel between hip implant maker DePuy and researcher Deborah Cohen may be more than an academic altercation playing out in the pages of the esteemed British Medical Journal - it may be a preview of things to come.
A battle rages on the pages of the British Medical Journal, with researchers warning that patients may have been exposed to toxic compounds and DePuy representatives calling the reports "unnecessarily alarmist."
While the DePuy ASR metal-on-metal hip recall has been playing out amid lawsuits and federal probes, another battle has been playing out on another, quieter front – the pages of the British Medical Journal.
